C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study

Thrombosis and Haemostasis

Volumn 95, Issue 3, 2006, Pages 511-518

  Tuomisto, Karolina ^a   Jousilahti, Pekka ^a   Sundvall, Jouko ^a   Pajunen, Pia ^a   Salomaa, Veikko ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Cardiovascular disease; Cytokines; Inflammation; Myocardial infarction

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FINLAND; FOLLOW UP; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SEX DIFFERENCE; STATISTICAL ANALYSIS;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FINLAND; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645538914     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-08-0571     Document Type: Article

References (46)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Pearson TA, Mensah GA, Alexander RW, et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
3. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BMJ 2000; 321: 199-204.
4. Cesari M, Penninx BWJH, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC Study. Circulation 2003; 108: 2317-22.
5. Ridker PM. High-sensitivity c-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-8.
6. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
7. Luc G, Bard JM, Juhan-Vague I, et al.; PRIME Study Group. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003; 23: 1255-61.
8. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women. The Cardiovascular Health Study. Circulation 2005; 112: 25-31.
9. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
10. Wilson PWF, Nam B-H, Pencina M, et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005; 165:2473-8.
11. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-610.
12. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
13. Vartiainen E, Puska P, Jousilahti P, et al. Twenty-year trends in coronary risk factors in North Karelia and in other areas of Finland. Int J Epidemiol 1994; 23: 495-504.
14. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988; 41: 105-14.
15. Salomaa V, Koukkunen H, Ketonen M, et al. for the FINAMI Study Group. A new definition for myocardial infarction: what difference does it make? Eur Heart J 2005; 26: 1719-25.
16. Sivenius J, Tuomilehto J, Immonen-Räihä P, et al.; FINSTROKE study. Continuous 15-year decrease in incidence and mortality of stroke in Finland: the FINSTROKE study. Stroke 2004; 35: 420-5.
17. Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12: 132-7.
18. Mähönen M, Salomaa V, Torppa J, et al. The validity of the routine mortality statistics on coronary heart disease in Finland: comparison with the FINMONICA MI register data for the years 1983-1992. Finnish multinational MONItoring of trends and determinants in CArdiovascular disease. J Clin Epidemiol 1999; 52: 157-66.
19. Leppälä JM, Virtamo J, Heinonen OP. Validation of stroke diagnosis in the National Hospital Discharge Register and the Register of Causes of Death in Finland. Eur J Epidemiol 1999; 15: 155-60.
20. Prentice RL. On the design of synthetic case-control studies. Biometrics 1986; 42: 301-10.
21. Berthier F, Lambert C, Genin C, et al. Evaluation of an automated immunoassay method for cytokine measurement using the Immulite immunoassay system. Clin Chem Lab Med 1999; 37: 593-9.
22. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994; 50: 1064-72.
23. Barlow WE, Ichikawa L, Rosner D, et al. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52: 1165-72.
24. SAS Institute Inc. User's Guide, Statistics, Version 8. Cary, USA: SAS Institute, 1999; vol 1. 3884 pp.
25. Jousilahti P, Vartiainen E, Alho H, et al. Opposite associations of cardbohydrate-deficient transferrin and γ-glutamyltransferase with prevalent coronary heart disease. Arch Intern Med 2002; 162: 817-21.
26. Ruttman E, Brant LJ, Concin H, et al; the Vorarlberg Health Monitoring and Promotion Program Study Group. ?-glutamyltransferase as a risk factor for cardiovascular disease mortality. An epidemiological investigation in a cohort of 163944 Austrian adults. Circulation 2005; 112: 2130-7.
27. Meisinger C, Lowel H, Heier M, et al; KORA Study Group. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005; 258: 527-35.
28. Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28: 2913-8.
29. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl Med 1997; 336: 973-9.
30. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
31. Lowe GD, Sweetnam PM, Yarnell JW, et al. C-reactive protein, fibrin d-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 2004; 24: 1957-62.
32. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100: 96-102.
33. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-7.
34. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-9.
35. Li SH, Szmitko PE, Weisel RD, et al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 2004; 109: 833-6.
36. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.
37. Hu FB, Meigs JB, Li TY, et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700.
38. Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler ThrombVasc Biol 2002; 22: 2066-71.
39. Lowe GDO, Rumley A, McMahon AD, et al. Interleukin-6, fibrin d-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529-34.
40. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288: 980-7.
41. Undar L, Ertugrul C, Altunbas H, et al. Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6. Thromb Haemost 1999; 81: 571-5.
42. Dugue B, Leppänen E. Short-term variability in the concentration of serum interleukin-6 and its soluble receptor in subjectively healthy persons. Clin Chem Lab Med 1998; 36: 323-5.
43. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53.
44. Koukkunen H, Penttilä K, Kemppainen A, et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 2001; 33: 37-47.
45. Vasan RS, Sullivan LM, Roubenoff R, et al.; Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107: 1486-91.
46. Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr 2005; 25: 151-74.